BlueDot, founded by H2i executive team member Kamran Khan, was featured in the latest issue of University of Toronto Magazine. The issue, titled AI Everywhere, profiles researchers from across the university and examines how they are working to shape a more positive future by leveraging the power of AI. BlueDot’s feature piece, A Sentinel for Global Health, profiles the venture’s work in using AI to track and predict disease outbreaks. BlueDot’s success to date, well-documented in media and academic journals alike, has demonstrated that AI is a strong complement to human expertise. Their impressive work has shown how AI can be harnessed to enhance the accuracy, speed and availability of crucial data needed to bolster emergency preparedness and improve health outcomes globally. Read A Sentinel for Global Health here

Congratulations to five H2i ventures who were recently announced as being among the first ten startups accepted into SpinUp, UofT Mississauga’s first wet-lab incubator. Mesosil, ImmunoBiochem, Epiloid Biotechnology, Bough Biosciences and Arma Biosciences will move into the newly-opened facility and have access to infrastructure, equipment and programming throughout their residency. With a focus on developing intellectual property and preparing for continued growth after graduation, SpinUP startups will have access to entrepreneurial education resources from across the three campuses. H2i congratulates these companies, as well as the SpinUP team for the launch of this exciting new chapter! Learn more about SpinUP and its resident companies on their website

H2i venture Paradox Immunotherapeutics has been selected as a finalist for the inaugural J.P. Morgan Life Sciences Innovation Summit! The announcement signals an impressive accomplishment for Paradox, as only 11 ventures were selected from a competitive pool of 150 applicants from more than 20 countries. Finalists will present their innovative work at the annual summit, which is hosted by J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors, United AlSaqer Group, and the Department of Health Abu Dhabi. This year’s summit will be held May 14th and 15th at Cleveland Clinic Abu Dhabi, as a part of the broader Abu Dhabi Global Healthcare Week.

Paradox is a biotech that uses a proven-successful drug discovery platform to combat protein misfolding diseases such as amyloidosis. Paradox designs and develops specialized antibodies that can selectively target and remove only the problematic/misfolded proteins while leaving the healthy proteins in your body completely untouched.

Congratulations and best of luck at the summit, Team Paradox!